A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin sanguinarine amiodarone chlorpromazine clomiphene dihydroergotamine dipyridamole emetine ephedrine prochlorperazine promazine propiomazine aminacrine fluphenazine fenoterol peruvoside proglumide atenolol nerifolin nefopam cycloheximide avermectin B1 bepridil cinnarizine ethisterone pararosaniline methylbenzethonium niclosamide p...

1. A pharmaceutical formulation which comprises in addition to at least one carrier diluent or adjuvant at least one neuroleptic compound in an amount effective to exert a neuroleptic effect in a patient requiring such treatment and melatonin in an amount effective to ameliorate or prevent symptoms of tardive dyskensia developing in the patient. 2. A pharmaceutical formulation according to claim 1 characterized by at least one of the following features: it is adapted for oral rectal parenteral o...

A water-dispersible veterinary preparation comprises (a) up to 50% by weight of a therapeutically active substance (b) from 2 to 70% by weight of a polyethyleneglycol which is solid at room temperature and (c) from 10 to 70% by weight of an amphiphilic agent which is solid at room temperature the preparation being in the form of particles the major portion of which have a diameter within the range of 50-200m . The polyethyleneglycol may have an average molecular weight of 2000-10000. The amphi...

A water-dispersible veterinary preparation comprises (a) up to 50% by weight of a therapeutically active substance (b) from 2 to 70% by weight of a polyethyleneglycol which is solid at room temperature and (c) from 10 to 70% by weight of an amphiphilic agent which is solid at room temperature the preparation being in the form of particles the major portion of which have a diameter within the range of 50-200m . The polyethyleneglycol may have an average molecular weight of 2000-10000. The amphi...